本帖最后由 老马 于 2012-1-13 21:20 编辑
: G, }& z* K" V* B* \* W1 r. N
t8 d5 H& S3 y: O1 ^爱必妥和阿瓦斯丁的比较
+ Y# u" y. }/ I+ Z) B; L @
. t" H+ c! J# b6 Q0 y$ @; r' lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/* r9 s1 `" z1 r$ N% A) M
1 m4 H B2 [6 Q7 t7 X2 Z9 V1 H; U4 n
. H9 K; `& a. b; H xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
d$ x3 C5 L' Z" j" T) y==================================================6 Q; ^. P" d8 E
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 ~+ a2 h% y3 U: V. C( g# pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: W$ y) _- u5 L4 Q- f$ f/ z9 ~Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 n$ q) b* l, ]) a# ?9 j/ K4 l. N
|
显身卡
4 K* r" p: m) n0 D
